BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23523610)

  • 1. Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target α5 integrin in colon cancer cells.
    Janouskova H; Ray AM; Noulet F; Lelong-Rebel I; Choulier L; Schaffner F; Lehmann M; Martin S; Teisinger J; Dontenwill M
    Cancer Lett; 2013 Aug; 336(2):307-18. PubMed ID: 23523610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
    Janouskova H; Maglott A; Leger DY; Bossert C; Noulet F; Guerin E; Guenot D; Pinel S; Chastagner P; Plenat F; Entz-Werle N; Lehmann-Che J; Godet J; Martin S; Teisinger J; Dontenwill M
    Cancer Res; 2012 Jul; 72(14):3463-70. PubMed ID: 22593187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma.
    Renner G; Janouskova H; Noulet F; Koenig V; Guerin E; Bär S; Nuesch J; Rechenmacher F; Neubauer S; Kessler H; Blandin AF; Choulier L; Etienne-Selloum N; Lehmann M; Lelong-Rebel I; Martin S; Dontenwill M
    Cell Death Differ; 2016 Apr; 23(4):640-53. PubMed ID: 26470725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells.
    Davaadelger B; Shen H; Maki CG
    PLoS One; 2014; 9(11):e110844. PubMed ID: 25380055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells.
    Hori T; Kondo T; Kanamori M; Tabuchi Y; Ogawa R; Zhao QL; Ahmed K; Yasuda T; Seki S; Suzuki K; Kimura T
    Cancer Lett; 2010 Jan; 287(1):98-108. PubMed ID: 19577358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
    Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
    Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 activation suppresses irinotecan metabolite SN-38-induced cell damage in non-malignant but not malignant epithelial colonic cells.
    Gunasegaran B; Neilsen PM; Smid SD
    Toxicol In Vitro; 2020 Sep; 67():104908. PubMed ID: 32502622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
    Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
    Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors.
    Aizu W; Belinsky GS; Flynn C; Noonan EJ; Boes CC; Godman CA; Doshi B; Nambiar PR; Rosenberg DW; Giardina C
    Biochem Pharmacol; 2006 Oct; 72(8):981-91. PubMed ID: 16949053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
    Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
    Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
    Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
    J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
    Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
    Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 inhibitors suppress integrin alpha5 expression in human lung carcinoma cells through activation of Erk: involvement of Sp1 and AP-1 sites.
    Han S; Roman J
    Int J Cancer; 2005 Sep; 116(4):536-46. PubMed ID: 15825163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers.
    Murillo CA; Rychahou PG; Evers BM
    Surgery; 2004 Aug; 136(2):143-9. PubMed ID: 15300173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutlin-3 induces BCL2A1 expression by activating ELK1 through the mitochondrial p53-ROS-ERK1/2 pathway.
    Lee SY; Choi HC; Choe YJ; Shin SJ; Lee SH; Kim HS
    Int J Oncol; 2014 Aug; 45(2):675-82. PubMed ID: 24867259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
    Shimazu K; Tada Y; Morinaga T; Shingyoji M; Sekine I; Shimada H; Hiroshima K; Namiki T; Tatsumi K; Tagawa M
    BMC Cancer; 2017 May; 17(1):309. PubMed ID: 28464864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.